In 2024, lung cancer treatment saw significant strides, including the approval of ensartinib for ALK-positive NSCLC and tarlatamab for SCLC. Advances also included December approvals, promising ADC ...
Investments in energy grid modernization and digitalization have not kept pace with energy demands and requirements over the past years. Given rapid electrification and the ongoing energy transition ...